Anzeige
Mehr »
Freitag, 05.09.2025 - Börsentäglich über 12.000 News
Set to Action: Q-Gold vor drastischer Neubewertung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CPAM | ISIN: US7867001049 | Ticker-Symbol: 0O2
Tradegate
02.09.25 | 18:17
6,300 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
SAGIMET BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
SAGIMET BIOSCIENCES INC 5-Tage-Chart
RealtimeGeldBriefZeit
6,1506,30004.09.
6,1006,30004.09.

Aktuelle News zur SAGIMET BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
22.08.Sagimet Biosciences Inc. - 8-K, Current Report2
13.08.Sagimet Biosciences Inc Q2 Loss Increases, But Beats Estimates3
13.08.Sagimet Biosciences GAAP EPS of -$0.32 beats by $0.214
13.08.Sagimet Biosciences Inc.: Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates378Denifanstat met all primary and secondary endpoints in Phase 3 clinical trial in moderate to severe acne conducted by license partner Ascletis in China Initiated first-in-human Phase 1 clinical trial...
► Artikel lesen
13.08.Sagimet Biosciences Inc. - 8-K, Current Report4
13.08.Sagimet Biosciences Inc. - 10-Q, Quarterly Report2
11.08.Wedbush initiates coverage on Sagimet Biosciences stock with Outperform rating4
24.07.Sagimet gains as Canaccord Genuity starts with Buy on potential against MASH12
SAGIMET BIOSCIENCES Aktie jetzt für 0€ handeln
17.06.Sagimet stock holds steady as JMP reiterates $31 price target20
09.06.Sagimet Biosciences Inc.: Sagimet Biosciences to Host Virtual KOL Event, "A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne" on June 16, 202512
04.06.Sagimet Biosciences Stock Gains 14% After Positive Phase 3 Acne Trial Results10
04.06.Sagimet's Partner Achieves Positive Results With Oral Acne Drug In Phase 3 Acne Trial In China, Stock Jumps6
04.06.Sagimet Biosciences shares soar on positive acne treatment trial results6
04.06.Sagimet climbs as acne therapy hits main goals in late-stage trial in China2
04.06.Why Sagimet Biosciences Is Rising In Pre-market?3
04.06.Sagimet Biosciences Inc. - 8-K, Current Report2
04.06.Sagimet Biosciences Inc.: Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis191Denifanstat met all primary and secondary endpoints versus placebo Denifanstat was well tolerated Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to...
► Artikel lesen
08.05.Sagimet Biosciences reports Q1 results7
08.05.Sagimet Biosciences Inc. - 8-K, Current Report5
08.05.Sagimet Biosciences Inc.: Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates621SAN MATEO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...
► Artikel lesen
Weiter >>
33 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2